.Attributes Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of people along with HER2+ advanced bosom cancer as well as active or even stable mind metastases presented regular intracranial task and also systemic effectiveness of T-DXd.